As reported by the National Health Executive, thousands of people living with multiple sclerosis (MS) are set to gain NHS access to the first medicine specifically licensed to improve walking difficulties, following a nationwide rollout announced by NHS England
The treatment, fampridine, will be routinely available for eligible patients and is expected to benefit around 5,000 people during its first year.
Mobility problems are among the most common and disabling symptoms of MS, often affecting independence, employment and everyday activities. Until now, support has largely focused on physiotherapy, mobility equipment and managing related symptoms such as muscle stiffness.
Fampridine offers a different approach by targeting the underlying nerve signalling affected by the condition. Taken twice a day as a tablet, the medicine helps damaged nerves transmit electrical signals more effectively, improving communication between the brain, spinal cord and muscles.
Evidence from clinical trials showed that 43% of patients experienced faster walking speeds after taking the drug. Some participants also reported being able to walk further, helping them carry out daily tasks and remain socially active.
Patients starting treatment will first complete a two to four-week assessment period. Walking ability will be measured before and after the trial, with only those who show a clear benefit continuing to receive the medication. Regular reviews will then monitor whether the treatment continues to deliver improvements over time.
Be the first to comment